T. Rowe Price Associates’s AIM ImmunoTech AIM Stock Holding History

T. Rowe Price Associates’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-203	Closed	-$9K	–	3044
2023 Q1	$9K	Sell	203 -955	-82%	-$49.5K	﹤0.01%	2888
2022 Q4	$36K	Hold	1,158	–	–	﹤0.01%	2850
2022 Q3	$68K	Sell	1,158 -11	-0.9%	-$770	﹤0.01%	2792
2022 Q2	$91K	Hold	1,169	–	–	﹤0.01%	2773
2022 Q1	$124K	Hold	1,169	–	–	﹤0.01%	2814
2021 Q4	$107K	Hold	1,169	–	–	﹤0.01%	2863
2021 Q3	$236K	Hold	1,169	–	–	﹤0.01%	2661
2021 Q2	$251K	Hold	1,169	–	–	﹤0.01%	2644
2021 Q1	$265K	Hold	1,169	–	–	﹤0.01%	2602
2020 Q4	$209K	Hold	1,169	–	–	﹤0.01%	2546
2020 Q3	$251K	Buy	+1,169	New	+$292K	﹤0.01%	2354

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates's AIM Position: Q2 2023 in Review

T. Rowe Price Associates sold out of AIM ImmunoTech (AIM) in Q2 2023, closing a stake of 203 shares — an estimated $9K sold.

T. Rowe Price Associates first reported a position in AIM in Q3 2020 and held it in 11 quarters. The position peaked at $265K in Q1 2021. 30 funds tracked by Wall St. Rank hold AIM as of Q2 2023.

T. Rowe Price Associates reported no remaining AIM ImmunoTech position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 203 AIM ImmunoTech shares in Q2 2023, an estimated $9K.
T. Rowe Price Associates first reported a position in AIM ImmunoTech in Q3 2020 and held it in 11 quarters.
T. Rowe Price Associates's AIM ImmunoTech position peaked at $265K in Q1 2021.
30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.